NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HL-22-032 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-101 from the NIH Guide for Grants and Contracts
Notice NOT-RM-22-017 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-029 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-090 from the NIH Guide for Grants and Contracts
Notice NOT-AG-22-026 from the NIH Guide for Grants and Contracts
Notice NOT-TW-22-004 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-088 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-031 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-198 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal the PAIRS program is to the development of radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.
Funding Opportunity PAR-22-199 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will solicit R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.
Funding Opportunity RFA-CA-22-026 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Center for International Blood and Marrow Transplant Research (CIBMTR) as a data resource enabling broad studies on Hematopoietic Stem Cell transplantation (HCT) and Adoptive Cellular Therapy (ACT) research. The CIBMTR represents a network comprised of more than 380 US and international transplant centers that submit outcome data for patients receiving cellular therapies. The CIBMTR Statistical Center provides data acquisition and management and information technology services to maintain a unique contemporary clinical outcomes' database and facilitates observational and interventional research through scientific and statistical expertise necessary to support analyses of these data. NIH is supporting the CIBMTR to ensure the database remains available to the public and to improve the treatment, survival, and quality of life for patients diagnosed with cancer and non-malignant blood disorders.
Notice NOT-DA-22-070 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-250 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-23-032 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to establish a network that will conduct transdisciplinary aging diagnostic biomarker and/or imaging research projects focused on Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) in persons living with Multiple Chronic Conditions (MCCs). The aim of the research is to better align diagnostic testing with the needs and priorities of an aging population. The national consortium will: 1) assemble existing data and acquire real-world data to ensure that the research sample is large and diverse, with adequate representation of older adults living with well-characterized MCCs, and incorporate pre-specified subgroup analyses; 2) analyze data for performance and accuracy of biomarkers, to include blood, cerebrospinal fluid (CSF), and imaging, in older patients living with MCCs; and 3) conduct pilot studies involving specific AD/ADRD imaging and/or biomarkers in persons living with MCCs.
Notice NOT-OD-22-154 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-011 from the NIH Guide for Grants and Contracts. oAs of May 18, 2021, 36 US states and four territories allow for the medical use of cannabis products. Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement. As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects. The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use. This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings.
Notice NOT-OD-22-082 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-084 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-083 from the NIH Guide for Grants and Contracts